Browsing by Author "Devleesschauwer, Brecht"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysisPublication . Cassini, Alessandro; Högberg, Liselotte Diaz; Plachouras, Diamantis; Quattrocchi, Annalisa; Hoxha, Ana; Simonsen, Gunnar Skov; Colomb-Cotinat, Mélanie; Kretzschmar, Mirjam E.; Devleesschauwer, Brecht; Cecchini, Michele; Ouakrim, Driss Ait; Oliveira, Tiago Cravo; Struelens, Marc J.; Suetens, Carl; Monnet, Dominique L.; Strauss, Reinhild; Mertens, Karl; Struyf, Thomas; Catry, Boudewijn; Latour, Katrien; Ivanov, Ivan N.; Dobreva, Elina G.; Tambic Andraševic, Arjana; Soprek, Silvija; Budimir, Ana; Paphitou, Niki; Žemlicková, Helena; Schytte Olsen, Stefan; Wolff Sönksen, Ute; Märtin, Pille; Ivanova, Marina; Lyytikäinen, Outi; Jalava, Jari; Coignard, Bruno; Eckmanns, Tim; Abu Sin, Muna; Haller, Sebastian; Daikos, George L.; Gikas, Achilleas; Tsiodras, Sotirios; Kontopidou, Flora; Tóth, Ákos; Hajdu, Ágnes; Guólaugsson, Ólafur; Kristinsson, Karl G.; Murchan, Stephen; Burns, Karen; Pezzotti, Patrizio; Gagliotti, Carlo; Dumpis, Uga; Liuimiene, Agne; Perrin, Monique; Borg, Michael A.; de Greeff, Sabine C.; Monen, Jos C.M.; Koek, Mayke B.G.; Elstrøm, Petter; Zabicka, Dorota; Deptula, Aleksander; Hryniewicz, Waleria; Caniça, Manuela; Nogueira, Paulo Jorge; Fernandes, Paulo André; Manageiro, Vera; Popescu, Gabriel A.; Serban, Roxana I.; Schréterová, Eva; Litvová, Slavka; Štefkovicová, Mária; Kolman, Jana; Klavs, Irena; Korošec, Aleš; Aracil, Belén; Asensio, Angel; Pérez-Vázquez, María; Billström, Hanna; Larsson, Sofie; Reilly, Jacqui S.; Johnson, Alan; Hopkins, SusanBackground: Infections due to antibiotic-resistant bacteria are threatening modern health care. However, estimating their incidence, complications, and attributable mortality is challenging. We aimed to estimate the burden of infections caused by antibiotic-resistant bacteria of public health concern in countries of the EU and European Economic Area (EEA) in 2015, measured in number of cases, attributable deaths, and disability-adjusted life-years (DALYs). Methods: We estimated the incidence of infections with 16 antibiotic resistance–bacterium combinations from European Antimicrobial Resistance Surveillance Network (EARS-Net) 2015 data that was country-corrected for population coverage. We multiplied the number of bloodstream infections (BSIs) by a conversion factor derived from the European Centre for Disease Prevention and Control point prevalence survey of health-care-associated infections in European acute care hospitals in 2011–12 to estimate the number of non-BSIs. We developed disease outcome models for five types of infection on the basis of systematic reviews of the literature. Findings: From EARS-Net data collected between Jan 1, 2015, and Dec 31, 2015, we estimated 671 689 (95% uncertainty interval [UI] 583 148–763 966) infections with antibiotic-resistant bacteria, of which 63·5% (426 277 of 671 689) were associated with health care. These infections accounted for an estimated 33 110 (28 480–38 430) attributable deaths and 874 541 (768 837–989 068) DALYs. The burden for the EU and EEA was highest in infants (aged <1 year) and people aged 65 years or older, had increased since 2007, and was highest in Italy and Greece. Interpretation: Our results present the health burden of five types of infection with antibiotic-resistant bacteria expressed, for the first time, in DALYs. The estimated burden of infections with antibiotic-resistant bacteria in the EU and EEA is substantial compared with that of other infectious diseases, and has increased since 2007. Our burden estimates provide useful information for public health decision-makers prioritising interventions for infectious diseases.
- Burden of Disease Methods: a Guide to Calculate COVID-19 Disability-Adjusted Life YearsPublication . Wyper, Grant; Assunção, Ricardo; Colzani, Edoardo; Grant, Ian; Haagsma, Juanita A; Lagerweij, Giske; Von der Lippe, Elena; McDonald, Scott A.; Pires, Sara; Porst, Michael; Speybroeck, Niko; Devleesschauwer, BrechtBackground: To date, most efforts to understand the comparative population health impact of COVID-19 have been made using mortality-based metrics. This has intensified discussion over methodological choices; in particular, how we value the life-years prematurely lost due to COVID-19. So far, the direct impact of COVID-19 on population health has varied across countries, with wide variation in incidence and infection fatality rates. Understanding and quantifying the combined impact of morbidity and mortality is a key step to standardizing comparisons across countries, and to quantify the within-country impact of COVID-19 relative to other causes of disease and injury, sub-national areas or demographics. This can be achieved by estimating summary measures of population health like disability-adjusted life years (DALYs). The estimation of DALYs is useful to provide comprehensive and comparative public health intelligence to inform decision-making for the management of the COVID-19 pandemic, particularly around the extent of direct and indirect consequences. At present, the Global Burden of Disease (GBD) study has not integrated COVID-19. Some studies have already estimated DALYs due to COVID-19. The first published assessment was performed for Korea, up until the end of April 2020. An assessment, using a similar time frame, followed for Italy. To date, published studies have only included one COVID-19 related health state, or disability weights were country-specific. Aim: Our paper provides a step-by-step guide to define COVID-19 as a cause of disease burden, which can be used to calculate DALYs. Additionally, we suggest pragmatic data inputs, reflecting that availability and quality of data inputs will vary by country. This paper builds on previous DALY calculation guides. As our paper provides suggestions for different solutions, we recommend that users should be clear about their methodological choices to aid comparisons and knowledge translation.
- Epidemiology of taeniosis/cysticercosis in Europe, a systematic review: Western EuropePublication . Laranjo-González, Minerva; Devleesschauwer, Brecht; Trevisan, Chiara; Allepuz, Alberto; Sotiraki, Smaragda; Abraham, Annette; Afonso, Mariana Boaventura; Blocher, Joachim; Cardoso, Luís; Correia da Costa, José Manuel; Dorny, Pierre; Gabriël, Sarah; Gomes, Jacinto; Gómez-Morales, María Ángeles; Jokelainen, Pikka; Kaminski, Miriam; Krt, Brane; Magnussen, Pascal; Robertson, Lucy J.; Schmidt, Veronika; Schmutzhard, Erich; Smit, G Suzanne A.; Šoba, Barbara; Stensvold, Christen Rune; Starič, Jože; Troell, Karin; Rataj, Aleksandra Vergles; Vieira-Pinto, Madalena; Vilhena, Manuela; Wardrop, Nicola Ann; Winkler, Andrea S.; Dermauw, VeroniqueBackground: Taenia solium and Taenia saginata are zoonotic parasites of public health importance. Data on their occurrence in humans and animals in western Europe are incomplete and fragmented. In this study, we aimed to update the current knowledge on the epidemiology of these parasites in this region. Methods: We conducted a systematic review of scientific and grey literature published from 1990 to 2015 on the epidemiology of T. saginata and T. solium in humans and animals. Additionally, data about disease occurrence were actively sought by contacting local experts in the different countries. Results: Taeniosis cases were found in twelve out of eighteen countries in western Europe. No cases were identified in Iceland, Ireland, Luxembourg, Norway, Sweden and Switzerland. For Denmark, Netherlands, Portugal, Slovenia, Spain and the UK, annual taeniosis cases were reported and the number of detected cases per year ranged between 1 and 114. Detected prevalences ranged from 0.05 to 0.27%, whereas estimated prevalences ranged from 0.02 to 0.67%. Most taeniosis cases were reported as Taenia spp. or T. saginata, although T. solium was reported in Denmark, France, Italy, Spain, Slovenia, Portugal and the UK. Human cysticercosis cases were reported in all western European countries except for Iceland, with the highest number originating from Portugal and Spain. Most human cysticercosis cases were suspected to have acquired the infection outside western Europe. Cases of T. solium in pigs were found in Austria and Portugal, but only the two cases from Portugal were confirmed with molecular methods. Germany, Spain and Slovenia reported porcine cysticercosis, but made no Taenia species distinction. Bovine cysticercosis was detected in all countries except for Iceland, with a prevalence based on meat inspection of 0.0002–7.82%. Conclusions: Detection and reporting of taeniosis in western Europe should be improved. The existence of T. solium tapeworm carriers, of suspected autochthonous cases of human cysticercosis and the lack of confirmation of porcine cysticercosis cases deserve further attention. Suspected cases of T. solium in pigs should be confirmed by molecular methods. Both taeniosis and human cysticercosis should be notifiable and surveillance in animals should be improved.
- Population vulnerability to COVID-19 in Europe: a burden of disease analysisPublication . Wyper, Grant M.A.; Assunção, Ricardo; Cuschieri, Sarah; Devleesschauwer, Brecht; Fletcher, Eilidh; Haagsma, Juanita A.; Hilderink, Henk B.M.; Idavain, Jane; Lesnik, Tina; Von der Lippe, Elena; Majdan, Marek; Milicevic, Milena S.; Pallari, Elena; Peñalvo, José L.; Pires, Sara M.; Plaß, Dietrich; Santos, João V.; Stockton, Diane L.; Thomsen, Sofie Theresa; Grant, IanBackground: Evidence has emerged showing that elderly people and those with pre-existing chronic health conditions may be at higher risk of developing severe health consequences from COVID-19. In Europe, this is of particular relevance with ageing populations living with non-communicable diseases, multi-morbidity and frailty. Published estimates of Years Lived with Disability (YLD) from the Global Burden of Disease (GBD) study help to characterise the extent of these effects. Our aim was to identify the countries across Europe that have populations at highest risk from COVID-19 by using estimates of population age structure and YLD for health conditions linked to severe illness from COVID-19. Methods: Population and YLD estimates from GBD 2017 were extracted for 45 countries in Europe. YLD was restricted to a list of specific health conditions associated with being at risk of developing severe consequences from COVID-19 based on guidance from the United Kingdom Government. This guidance also identified individuals aged 70 years and above as being at higher risk of developing severe health consequences. Study outcomes were defined as: (i) proportion of population aged 70 years and above; and (ii) rate of YLD for COVID-19 vulnerable health conditions across all ages. Bivariate groupings were established for each outcome and combined to establish overall population-level vulnerability. Results: Countries with the highest proportions of elderly residents were Italy, Greece, Germany, Portugal and Finland. When assessments of population-level YLD rates for COVID-19 vulnerable health conditions were made, the highest rates were observed for Bulgaria, Czechia, Croatia, Hungary and Bosnia and Herzegovina. A bivariate analysis indicated that the countries at high-risk across both measures of vulnerability were: Bulgaria; Portugal; Latvia; Lithuania; Greece; Germany; Estonia; and Sweden. Conclusion: Routine estimates of population structures and non-fatal burden of disease measures can be usefully combined to create composite indicators of vulnerability for rapid assessments, in this case to severe health consequences from COVID-19. Countries with available results for sub-national regions within their country, or national burden of disease studies that also use sub-national levels for burden quantifications, should consider using non-fatal burden of disease estimates to estimate geographical vulnerability to COVID-19.